<SEC-DOCUMENT>0001144204-19-046508.txt : 20190930
<SEC-HEADER>0001144204-19-046508.hdr.sgml : 20190930
<ACCEPTANCE-DATETIME>20190930160226
ACCESSION NUMBER:		0001144204-19-046508
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190930
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190930

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cellectar Biosciences, Inc.
		CENTRAL INDEX KEY:			0001279704
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043321804
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36598
		FILM NUMBER:		191126134

	BUSINESS ADDRESS:	
		STREET 1:		100 CAMPUS DRIVE
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932
		BUSINESS PHONE:		(608) 441-8120

	MAIL ADDRESS:	
		STREET 1:		100 CAMPUS DRIVE
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVELOS THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050617

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COMMON HORIZONS INC
		DATE OF NAME CHANGE:	20040211
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv530304_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B><BR>
Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">___________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">___________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):
<B>September 30, 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B>CELLECTAR
BIOSCIENCES, INC.</B></FONT><BR>
(<I>Exact name of registrant as specified in charter</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; padding-right: 0.2in; padding-left: 0.2in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Delaware</B></P></TD>
    <TD STYLE="width: 34%; padding-right: 0.2in; padding-left: 0.2in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>1-36598</B></P></TD>
    <TD STYLE="width: 33%; padding-right: 0.2in; padding-left: 0.2in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>04-3321804</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(State or other jurisdiction</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>of incorporation)</I></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Commission</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>File Number)</I></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(I.R.S. Employer</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Identification No.)</I></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>100 Campus Drive, Florham Park, New Jersey
07932</B><BR>
(<I>Address of principal executive offices, and zip code</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(608) 441-8120<BR>
</B>(<I>Registrant's telephone number, including area code</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communication
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communication
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &sect;230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (17 CFR &sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 16%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name of each exchange on which registered</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Common stock, par value $0.00001</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Warrant to purchase common stock, expiring
        April 20, 2021</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CLRB</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CLRBZ</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NASDAQ Capital Market</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NASDAQ Capital Market&nbsp;</P></TD></TR>
</TABLE>
<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.75pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-size: 10pt"><B>ITEM 7.01</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>REGULATION FD DISCLOSURE</B></FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">On September 30, 2019, we issued a press release <FONT STYLE="color: #050505">announcing
that Jarrod Longcor, our chief business officer, presented data from the diffuse large B cell lymphoma (DLBCL) cohort in our Phase
2 CLOVER-1 study of CLR 131 in relapsed or refractory select B-cell malignancies at the European Society for Medical Oncology (ESMO)
Congress 2019 being held from September 27 &ndash; October 1, 2019 in Barcelona, Spain.</FONT>. A copy of the press release is
furnished as Exhibit 99.1 and is incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-size: 10pt"><B>ITEM 9.01</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>FINANCIAL STATEMENTS
AND EXHIBITS</B></FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Number</FONT></TD>
    <TD STYLE="width: 2%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 88%; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Title</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><A HREF="tv530304_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><A HREF="tv530304_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Press release dated September 30, 2019, titled &ldquo;Cellectar Presents Data from DLBCL Cohort of its Phase 2 CLOVER-1 Study at the European Society for Medical Oncology (ESMO) Congress&rdquo;</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">SIGNATURE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Dated:&nbsp;&nbsp;September 30, 2019&nbsp;&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>CELLECTAR BIOSCIENCES, INC.</B></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 50%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 3%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 5%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 30%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 12%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Dov Elefant</I></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Name:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Dov Elefant</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Title:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv530304_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: right; text-indent: 0.5in; background-color: white"><FONT STYLE="font-size: 14pt"><B><IMG SRC="image_001.jpg" ALT="" STYLE="height: 54.75pt; width: 174pt"></B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Cellectar Presents
Data from DLBCL Cohort of its Phase 2 CLOVER-1 Study at the European Society for Medical Oncology (ESMO) Congress</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I>Data showed
durable clinical responses, including a 33% overall response rate (ORR) and 16.6% complete response (CR)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>FLORHAM PARK,
N.J., September 30, 2019</B>&nbsp;<B>--&nbsp;Cellectar Biosciences, Inc.&nbsp;(NASDAQ: CLRB)</B>, a clinical-stage biopharmaceutical
company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced Jarrod
Longcor, chief business officer of Cellectar, presented data from the diffuse large B cell lymphoma (DLBCL) cohort in the company&rsquo;s
Phase 2 CLOVER-1 study of CLR 131 in relapsed or refractory select B-cell malignancies at the European Society for Medical Oncology
(ESMO) Congress 2019 being held from September 27 &ndash; October 1, 2019 in Barcelona, Spain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The oral presentation,
entitled: &ldquo;<I>Interim Evaluation of a Targeted Radiotherapeutic, CLR 131, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Patients (R/R DLBCL),</I>&rdquo; featured data from 6 subjects who received a single 30-minute intravenous (IV) dose of <FONT STYLE="background-color: white">25mCi/m<SUP>2</SUP></FONT>
of CLR 131. Data showed durable responses, including a 33% overall response rate (ORR), a 16.6% complete response rate (CR) and
a 50% clinical benefit rate (CBR). All patients enrolled in the study received an average of 3 prior lines of systemic therapy,
5 of 6 patients were refractory to at least one prior line of therapy. Importantly, CLR 131 showed activity against both germinal
center and activated DLBCL. In a patient for whom cytogenetics was available, CLR 131 showed activity against c-Myc and BCL-2 mutation
(single &amp; dual-hit) positive patients. As required by the Lugano Criteria for Response, the patient who experienced a CR had
a total reduction in tumor volume of greater than 99% and continues to be a CR at 510+ days post dosing. This patient was refractory
to two prior treatment lines, which included the combination regimen RICE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Analysis of dosing
showed that the disease control rate and progression free survival were markedly improved in patients receiving a dosing ratio
of 1.2% or greater (drug to tumor volume) versus those receiving below a 1.2% dosing ratio. Finally, the most frequent adverse
events (AE) in DLBCL patients were consistent with prior studies of CLR 131; the majority of AEs being hematologic in nature and
predominately Grades 1 and 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&ldquo;The data
presented show an encouraging overall response rate including a complete response at the time of the interim assessment after a
single 30-minute IV dose of <FONT STYLE="background-color: white">25mCi/m<SUP>2</SUP> of CLR 131</FONT>. We remain optimistic that
CLR 131 has the potential to provide a meaningful treatment option for a variety of lymphoma patients and look forward to reporting
additional data from this Phase 2 CLOVER-1 study in 2019,&rdquo; said James Caruso, president and CEO of Cellectar. &ldquo;The
study remains ongoing and, based on this cohort and additional data from an ongoing dose escalation Phase 1 study, patients in
the Phase 2 CLOVER-1 study are now receiving a higher 37.50 mCi/m<SUP>2</SUP> fractionated dose administered in two 30-minute infusions
of 18.75mCi/m<SUP>2</SUP>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About the Phase 2 CLOVER-1 Trial&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">CLOVER-1 is a
Phase 2 study of CLR 131 being conducted in approximately 10 leading cancer centers in the United States in patients with relapsed
or refractory B-cell hematologic cancers. The hematologic cancers being studied in the trial include multiple myeloma (MM), chronic
lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), mantle
cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The study will
enroll up to 80 patients. Its primary endpoint is clinical benefit response (CBR), with additional endpoints of overall response
rate (ORR), progression free survival (PFS), median overall survival (OS) and other markers of efficacy following a fractionated
dose of 37.575mCi/m<SUP>2</SUP>&nbsp;of CLR 131 administered in two 30-minute infusions of 18.75mCi/m<SUP>2</SUP>&nbsp;of CLR 131
administered on day 1 and day 8, with the option for a second dose cycle approximately 75-180 days later. The company expects to
report topline data in 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Cellectar was
awarded approximately $2 million in non-dilutive grant funding from the National Cancer Institute to help fund the trial. More
information about the trial, including eligibility requirements, can be found at&nbsp;<U>www.clinicaltrials.gov</U>, reference
NCT02952508.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About CLR 131</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CLR 131 is a small-molecule, cancer-targeting
radiotherapeutic Phospholipid Drug Conjugate<SUP>TM</SUP> (PDC) designed to deliver cytotoxic radiation directly and selectively
to cancer cells and cancer stem cells. CLR 131 is the company&rsquo;s lead therapeutic PDC product candidate and is currently being
evaluated in both Phase 2 and Phase 1 clinical studies. The FDA granted orphan drug designation for CLR 131 for the treatment of
multiple myeloma as well as orphan drug and rare pediatric disease designations for CLR 131 for the treatment of neuroblastoma,
rhabdomyosarcoma, Ewing&rsquo;s sarcoma and osteosarcoma. In addition to the ongoing Phase 1 dose-escalation study and the Phase
2 (CLOVER-1) trial, the company recently initiated a Phase 1 open-label, dose-escalating study in pediatric solid tumors and lymphoma
to evaluate the safety and tolerability of a single intravenous administration of CLR 131 in up to 30 children and adolescents
with cancers including neuroblastoma, sarcomas, lymphomas (including Hodgkin&rsquo;s lymphoma) and malignant brain tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>About Cellectar
Biosciences, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Cellectar Biosciences
is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing
proprietary drugs independently and through research and development (R&amp;D) collaborations. The company&rsquo;s core objective
is to leverage its proprietary Phospholipid Drug Conjugate<SUP>TM</SUP> (PDC) delivery platform to develop PDCs that specifically
target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company&rsquo;s
PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and
it plans to develop PDCs independently and through research and development collaborations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The company&rsquo;s
lead PDC therapeutic, CLR 131, is currently in three clinical studies &ndash; a Phase 2 study, and two Phase 1 studies. The Phase
2 clinical study (CLOVER-1) is in relapsed/refractory (R/R) B-cell malignancies, including multiple myeloma (MM), chronic lymphocytic
leukemia/small lymphocytic lymphoma (CLL/SLL), lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), mantle cell lymphoma
(MCL), and diffuse large B-cell lymphoma (DLBCL). The company is also conducting a Phase 1 dose escalation study in patients with
R/R multiple myeloma (MM) and a Phase 1 study in pediatric solid tumors and lymphoma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The company&rsquo;s
product pipeline also includes one preclinical PDC chemotherapeutic program (CLR 1900) and several partnered PDC assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">For more information,
please visit <FONT STYLE="color: Blue"><U>www.cellectar.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statement Disclaimer
&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This news release
contains forward-looking statements. You can identify these statements by our use of words such as &quot;may&quot;, &quot;expect&quot;,
&quot;believe&quot;, &quot;anticipate&quot;, &quot;intend&quot;, &quot;could&quot;, &quot;estimate&quot;, &quot;continue&quot;,
&quot;plans&quot;, or their negatives or cognates. These statements are only estimates and predictions and are subject to known
and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements
made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development
involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related
to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of CLR 131, the
ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development
thereof, the completion of clinical trials, the FDA review process and other government regulation, the volatile market for priority
review vouchers, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition
from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties
related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form
10-K for the year ended December 31, 2018 and Form 10-Q for the quarters ended March 31, 2019 and June 30, 2019. These forward-looking
statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Contacts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Investors:
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Monique Kosse</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Managing Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">LifeSci Advisors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">646-915-3820</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Blue"><U>monique@lifesciadvisors.com</U></FONT></P>



<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; text-align: left"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "S C<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^ND7_H8J:24II,JHW&#:,J/XK7\T22Q>#-3>-P&5U+$,#T(.SD4[_A:.I?\
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M=2^;(!_<7IGZL1_WS7A]>K@HVIW[GF8R5ZENP5]6^&H3;^%='A;[T=E"A_!
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M^$/^@W%_W[?_ .)JAX<^&>A6.@VL.J:;!=7^S=/(^3\QY('L.GX5J_\ "O\
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MPAVR]?PM(0\I5YX79MZ < 8;MR>>>O6J7_"W-%>$J^D:P9#\IA-NIR?^^O\
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@H **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
